Atom Bioscience raises $83M in Series D for URAT1 inhibitor in chronic gout treatment
Atom Bioscience has pulled in $83 million in Series D financing for its URAT1 inhibitor for chronic gout, the company announced Monday, with the money going toward finishing its pivotal trials for the drug.
The Chinese company has raised $165 million total over its financing rounds, thanks to investors like Kaitai Capital, Fortune Capital, Huajin Investment, Unifortune and NNFE Investment.
Atom touted ABP-671’s ability to reduce serum uric acid levels in urine by inhibiting URAT1, the primary endpoint in trials. Chronic gout is caused by elevated levels of the acid, also known as hyperuricemia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.